Eli Lilly: promising new results for mirikizumab
(CercleFinance.com) - Eli Lilly reports that a pivotal Phase III study has showed that patients with ulcerative colitis (UC) who responded to mirikizumab at 12 weeks achieved and maintained statistically superior and clinically meaningful improvements at one year compared to placebo.
As a result, 50% of patients with ulcerative colitis treated with mirikizumab achieved clinical remission at one year in this study.
In Q1 2022, Eli Lilly submitted a Biologics License Application (BLA) to the US FDA and a Marketing Authorization Application (MAA) in the European Union for the approval of mirikizumab in EC. Regulatory decisions in the US, EU and other countries are expected in 2023.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
As a result, 50% of patients with ulcerative colitis treated with mirikizumab achieved clinical remission at one year in this study.
In Q1 2022, Eli Lilly submitted a Biologics License Application (BLA) to the US FDA and a Marketing Authorization Application (MAA) in the European Union for the approval of mirikizumab in EC. Regulatory decisions in the US, EU and other countries are expected in 2023.
Copyright (c) 2022 CercleFinance.com. All rights reserved.